Oncology Hub

Jun
24

Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape

Breast cancer (BC) is a heterogeneous disease with human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification observed in 20%-30% of cases. HER2-positive (+) BC correlates with poor clinical outcomes unless appropriately treated with targeted therapy. Despite significant therapeutic advances, many patients experience disease progression with resistance to targeted agents developing over the course […]

Read More
DETAIL
May
15

Real-World Evidence: Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer

Participate in this free CME Snack to hear Dr. Martine Piccart discuss randomized, controlled trials, real-world data, and real-world evidence, focusing on the current real-world evidence in the field of cylcin-dependent kinase (CDK) 4/6 inhibitors in metastatic breast cancer. Earn CME/CE credit in just 20 minutes!

Read More
DETAIL